Immune Design Corp. (NASDAQ:IMDZ) is scheduled to post its quarterly earnings results after the market closes on Wednesday, November 1st. Analysts expect Immune Design Corp. to post earnings of ($0.63) per share for the quarter.

Immune Design Corp. (NASDAQ:IMDZ) last posted its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.11. The company had revenue of $0.73 million during the quarter, compared to analysts’ expectations of $1.50 million. Immune Design Corp. had a negative return on equity of 59.14% and a negative net margin of 324.33%. On average, analysts expect Immune Design Corp. to post $-2.27 EPS for the current fiscal year and $-2.34 EPS for the next fiscal year.

Immune Design Corp. (IMDZ) traded up 11.585% during mid-day trading on Monday, reaching $4.575. The company’s stock had a trading volume of 1,926,208 shares. The firm has a 50-day moving average of $9.13 and a 200 day moving average of $8.49. Immune Design Corp. has a 1-year low of $3.78 and a 1-year high of $13.05. The firm’s market capitalization is $117.21 million.

COPYRIGHT VIOLATION NOTICE: This report was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at

Several research analysts recently weighed in on IMDZ shares. Wells Fargo & Company lowered Immune Design Corp. from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $29.00 to $10.00 in a research report on Tuesday, October 17th. Zacks Investment Research raised Immune Design Corp. from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a research report on Tuesday, July 18th. ValuEngine lowered Immune Design Corp. from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 21st. Royal Bank Of Canada assumed coverage on Immune Design Corp. in a research report on Thursday, September 14th. They issued an “outperform” rating and a $20.00 target price on the stock. Finally, BidaskClub lowered Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 5th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $14.75.

In related news, Director Franklin M. Berger purchased 25,000 shares of the firm’s stock in a transaction dated Wednesday, October 25th. The stock was bought at an average price of $4.26 per share, for a total transaction of $106,500.00. Following the purchase, the director now owns 50,000 shares in the company, valued at approximately $213,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Wayne Gombotz sold 10,000 shares of the company’s stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $11.43, for a total value of $114,300.00. Following the sale, the insider now owns 33,054 shares of the company’s stock, valued at approximately $377,807.22. The disclosure for this sale can be found here. In the last quarter, insiders have bought 2,786,000 shares of company stock valued at $11,535,500. 20.70% of the stock is currently owned by corporate insiders.

An institutional investor recently raised its position in Immune Design Corp. stock. California State Teachers Retirement System lifted its stake in shares of Immune Design Corp. (NASDAQ:IMDZ) by 8.3% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 30,174 shares of the biotechnology company’s stock after acquiring an additional 2,300 shares during the quarter. California State Teachers Retirement System owned about 0.12% of Immune Design Corp. worth $294,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 51.44% of the company’s stock.

Immune Design Corp. Company Profile

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Earnings History for Immune Design Corp. (NASDAQ:IMDZ)

Receive News & Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related companies with's FREE daily email newsletter.